MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: In Press PR Ltd
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

New Range of Recombinant Fab Monoclonal Antibodies Launched at AACC 2013 - The AACC Conference and Expo sees the launch of an innovative new range of recombinant Fab monoclonal antibodies from BBI Solutions - AACC.org / BBISolutions.com
New Range of Recombinant Fab Monoclonal Antibodies Launched at AACC 2013

 

NewswireToday - /newswire/ - Cardiff, Wales, United Kingdom, 2013/07/16 - The AACC Conference and Expo sees the launch of an innovative new range of recombinant Fab monoclonal antibodies from BBI Solutions - AACC.org / BBISolutions.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

BBI Solutions, a world leader in immunoassay development and contract manufacturing, will launch its unique range of Recombinant Fab Monoclonal Antibodies on booth #3363 at the American Association for Clinical Chemistry’s (AACC) Annual Meeting and Clinical Lab Expo, on July 28-August 31, 2013, in Houston, Texas. These matched antibodies pairs, developed using proprietary phage display selection and the Luminex platform, exhibit sub-nanomolar affinities, exceptional sensitivity, and provide assay developers with clinically relevant performance characteristics to 34 biomarkers, with more in development.

The new Recombinant Fab Mouse Monoclonal Antibodies from BBI Solutions exhibit significant advantages over standard mouse monoclonal antibodies. From the screening process to testing in patient samples to ensure clinical significance, BBI Solutions’ methodology ensures that companies developing new assays have the most sensitive and reliable antibodies available in the market.

Because these new antibodies are grown in and purified from E. coli cultures, production is much quicker and more reliable than standard cell culture techniques, and large scale production is not an issue.

In regard to the new range, Dr. James Steggles, Commercial Manager at BBI Solutions, says,“Here at BBI Solutions it is our aim to ensure that we supply the market with antibodies that have world-class performance and give our customers significant advantages over their competitors. Each antibody pair is the best from a billion clones screened and 4500 matched pairs tested. By using this new range of monoclonal antibodies, they can produce clinical assays that are more sensitive and reliable than their competitors, as well as more cost-effective due to reduced R&D costs.”

BBI Solutions scientists (bbisolutions.com) will be at the AACC Conference to discuss the development of new products and any specific requirements customers may have.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: In Press PR Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


New Range of Recombinant Fab Monoclonal Antibodies Launched at AACC 2013

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Julie Hart - BBISolutions.com 
+44(0)29 2074 7232 info[.]bbisolutions.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any In Press PR Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From In Press PR Ltd / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-small Cell Lung Cancer
Stevanato Group, SCHOTT, and Gerresheimer Confirm the Readiness to Support Future Covid-19 Vaccine with Pharmaceutical Containers
Ipsen Receives FDA Fast Track Designation for Liposomal Irinotecan (ONIVYDE®) as A First-line Combination Treatment for Metastatic Pancreatic Cancer
Ipsen Demonstrates Continued Commitment to Rare Diseases with Eight Abstracts Accepted At ENDO 2020 Published in the Journal of the Endocrine Society
Waters Corporation Earns New Product Innovation Award with First SmartMS-enabled Biopharmaceutical Solution
DSM Boosts Maternal and Infant Nutrition Portfolio with New Plant-based High Potency DHA Oil
Ipsen Enters into an Option Agreement with IRICoR and Université de Montréal for A Discovery-stage Oncology Program
Ipsen Announces Positive Topline Results from Pivotal Phase III CheckMate -9ER Trial Evaluating CABOMETYX®
Ipsen Data Presented During ENETS Annual Conference 2020 Capture New Patient and Healthcare Professional Insights in the Treatment of NETs
Global Pharmaceutical Contract Manufacturing Organization Market to Reach 2.14 Billion by 2024 Finds Frost & Sullivan
Ipsen’s Palovarotene Clinical Program in Fibrodysplasia Ossificans Progressiva Reaches Prespecified Interim Analysis Futility Criteria
Global Bio-based Chemicals Market is Expected to Grow At A CAGR of 16.67% by 2027 According to Inkwood Research
Global Diabetes Drugs Market Forecast 2019-2027 Reports Inkwood Research
Dysport® Now Approved in the UK for Symptomatic Treatment of Upper Limb Spasticity in Children with Cerebral Palsy
Human Microbiome Market to Reach .08 Billion by 2023, Powered by the High Growth in Over-the-Counter Probiotics Finds Frost & Sullivan

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit Apex Watercraft

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2020 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)